SOURCE: HealthSonix, Inc.

August 28, 2007 08:01 ET

HealthSonix Sampling Program for ZingiberRx Pain Relieving Cream Draws Positive Reviews

IRVINE, CA--(Marketwire - August 28, 2007) - HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that a sampling program for its ZingiberRx pain relieving cream is underway and that the product is being received with a great deal of enthusiasm, particularly among sports enthusiasts and the still active over 50 crowd suffering with chronic pain and stiffness in their joints.

"We are getting a flood of positive reviews from people who have tried ZingiberRx," said Dieter D. Doederlein, Vice President of Corporate Development for HealthSonix. "We had high expectations for the product, and the results to date indicate that our expectations will be exceeded."

ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.

The company encourages Individuals, as well as shareholders, who experience chronic or acute pain to participate in the sampling program by ordering a free sample of Zingiber Rx by sending a "free sample request" email to INFO@HEALTHSONIX.COM or by calling the Company tool free at 1-877-622-2121. Orders may be placed on line at:

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information